Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q86YH6
UPID:
DLP1_HUMAN
Alternative names:
All-trans-decaprenyl-diphosphate synthase subunit 2; Candidate tumor suppressor protein; Decaprenyl pyrophosphate synthase subunit 2; Decaprenyl-diphosphate synthase subunit 2; Solanesyl-diphosphate synthase subunit 2
Alternative UPACC:
Q86YH6; Q33DR4; Q4G158; Q5VU38; Q5VU39; Q9NR58
Background:
All trans-polyprenyl-diphosphate synthase PDSS2, also known as Decaprenyl-diphosphate synthase subunit 2, plays a crucial role in the biosynthesis of coenzyme Q10 (CoQ10). This enzyme catalyzes the condensation of farnesyl diphosphate (FPP) and isopentenyl diphosphate (IPP) to produce prenyl diphosphates, essential for CoQ10 synthesis. CoQ10 is vital for mitochondrial respiratory chain function and cellular energy production.
Therapeutic significance:
Mutations in PDSS2 are linked to Coenzyme Q10 deficiency, primary, 3, a fatal disorder affecting the brain, muscles, and kidneys. Understanding PDSS2's role could lead to novel treatments for this and related mitochondrial diseases, highlighting its potential in therapeutic strategies.